FANGSHIZHEN CAPITAL
FANGSHIZHEN CAPITAL
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-07-22 | MAXVAX | Fangshizhen Capital investment in Series B - MAXVAX | 500 M CNY |
More informations about "Fangshizhen Capital"
Fangshizhen Capital - Investments, Portfolio & Company Exits
Fangshizhen Capital is a venture capital investment firm.See details»
Chinese Biotechs Garner Millions for Shingles Vaccine Candidate โฆ
Jul 22, 2022 Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led by China Life Private Equity Investment, with support from โฆSee details»
Fangshizhen Capital - Updates, News, Events, Signals & Triggers
Fangshizhen Capital is a venture capital investment firm.See details»
Vaccines Developer Maxvax Closes a Nearly CNY 500 Million โฆ
Jul 21, 2022 Fangshizhen Capital and Xinshang Capital, two new investors, also participated in this round. Maxvax plans to use the funds to conduct clinical trials of multiple vaccine โฆSee details»
Fangshizhen Capital โ 1 Investments, Exits, 1 Portfolio companies ...
Fangshizhen Capital. Search. Overview Investments Unlock datapoints. Portfolio analytics Team News & Media. Add fund to favorites. Save this fund for later to form your own custom list of โฆSee details»
Maxvax Completes $74 Million Series B for China Vaccine โฆ
Jul 28, 2022 Chengduโs Maxvax raised $74 million in a Series B round to support clinical trials of several pipeline vaccine candidates, including herpes zoster and rotavirus for neonates and โฆSee details»
Chengdu Maxvax Biotechnology LLC - Drug pipelines, Patents
Maxvax Raises $74 Million To Expand Chinese Operations Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led by China Life โฆSee details»
K193 bispecific antibody(Beijing Lüzhu Biotechnology)
Dec 7, 2024 Originator Organization. Beijing Lüzhu Biotechnology Co., Ltd. Active Organization. Beijing Lüzhu Biotechnology Co., Ltd. Inactive Organization-Drug Highest Phase Phase 1. โฆSee details»
ZhenFund - Wikipedia
ZhenFund (Chinese: ็ๆ ผๅบ้; pinyin: Zhฤngé jฤซjฤซn) is a Beijing-based venture capital firm founded in 2011 by New Oriental co-founders Bob Xu and Victor Wang. It is considered one of โฆSee details»
Shadow Banking Giant Zhongzhi and 247 Affiliated Firms Face ...
Jul 2, 2024 An investigation by the administrator found that Zhongzhi and the 247 affiliated entities share overlapping legal identities and assets, according to a court document from the โฆSee details»
Beijing Lüzhu Biotechnology Co., Ltd. - Drug pipelines, Patents ...
Maxvax Raises $74 Million To Expand Chinese Operations Vaccines developer Maxvax raised nearly CNY500 million (approx. $74 million) from a Series B funding round led by China Life โฆSee details»
Fiera Capital Company Description - Stock Analysis
Fiera Capital Corporation is an employee owned investment manager. The firm primarily provides its services to institutional investors, mutual funds, charitable organizations, and private โฆSee details»
Fangshizhen Capital - Crunchbase
Fangshizhen Capital is a venture capital investment firm.See details»
NATIONAL EMPLOYERS HUMAN CAPITAL ORGANIZATION LLC
Oct 2, 2024 NATIONAL EMPLOYERS HUMAN CAPITAL ORGANIZATION LLC is a Pennsylvania Foreign Limited-Liability Company filed on December 17, 2021. The company's โฆSee details»
MAXVAX - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial โฆSee details»
Series B - MAXVAX - 2022-07-22 - Crunchbase Funding Round โฆ
Jul 22, 2022 Organization Name . MAXVAX . Announced Date Jul 22, 2022; Funding Type Series B; Funding Stage Early Stage Venture; Money Raised . CN¥500M. Lead Investors. Edit โฆSee details»
ITC Conditions You Should Know Before Claiming ITC Under GST
6 days ago Input Tax Credit (ITC) is a vital feature of the GST system, allowing taxpayers to claim credit for the GST paid on purchases or expenses against the GST liability on their โฆSee details»
EK193 - Drug Targets, Indications, Patents - Synapse - Patsnap
EK193: a CD19 inhibitors, CD3 stimulants Drug, Initially developed by Beijing Lüzhu Biotechnology Co., Ltd., Now, its global highest R&D status is Preclinical, Mechanism: CD19 โฆSee details»
Star 26 Capital - Crunchbase Company Profile & Funding
Dec 15, 2024 Contact Email [email protected] Phone Number 646.257.4214 Star 26 Capital is a unique acquisition holding company that operates in the defense technology sector.See details»